Search

News Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy –⁠ Results of the Final Analysis of Clinical Studies

Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic and intracranial) and simultaneously improved median progression-free survival. Additional results presented at this year's ASCO congress included the final outcomes of studies focusing on the administration of brigatinib specifically in patients refractory to crizotinib therapy.

Source: Non-Small Cell Lung Cancer 9. 9. 2021

News Evaluation of Continuity of Care in Patients with mCRC –⁠ Baseline Characteristics of Participants in the PROMETCO Study

During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which focuses on evaluating the continuity of care in patients with metastatic colorectal cancer (mCRC), were presented.

Source: Treatment of Gastrointestinal Carcinomas 9. 9. 2021

News Optimization of Romiplostim Administration in ITP Treatment

In their newly published review article, authors from several American institutions summarize findings on the role of romiplostim in the treatment of immune thrombocytopenia (ITP) and its efficacy and safety. Among other things, they provide the latest data on its early administration as early as 3 months after the onset of the disease, discuss the possibility of achieving remission without the need for further treatment, and also address practical aspects of therapy.

Source: Immune Thrombocytopenia 22. 10. 2021

News HAE and its Management in Pediatric Patients

Hereditary angioedema (HAE) can be encountered in the emergency room as well as in specialist practices. Patients with this rare disease are often incorrectly diagnosed with other, more common conditions, and it can take many years before they receive the correct diagnosis. This is because the symptoms of HAE overlap with those of other illnesses. What should pediatricians, otolaryngologists, and gastroenterologists be aware of? To provide a better understanding of HAE symptoms from the perspective of various specialties and emphasize the importance of interdisciplinary collaboration for the correct diagnosis and care of patients with HAE, a professional webinar was held. We have prepared a summary of the most important points for you.

Source: Hereditary Angioedema 19. 11. 2021

News Heart Failure in Light of New ESC Guidelines

Dear Doctor, The Czech Society of Internal Medicine ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd at 5 PM.
You can find more information in the attached invitation below.

Source: Anticoagulant Treatment 27. 10. 2021

News Impact of Primary Tumor Location and Early Regression on Survival in Patients with Metastatic CRC

Results from recent clinical studies suggest the prognostic significance of the primary tumor location on the survival of patients with metastatic colorectal cancer (mCRC). A retrospective analysis of data from a single-arm open-label phase II clinical trial evaluated the impact of primary tumor location and its early regression (ETS -⁠ early tumor shrinkage) on the survival of patients with mCRC who received a combination of chemotherapy (FOLFIRI regimen) and targeted biological therapy (panitumumab).

Source: Colorectal Cancer 15. 9. 2020

News Romiplostim in Routine Clinical Use among Patients with ITP in European Countries −⁠ Fresh Data Analysis

Data from randomized clinical trials have shown that romiplostim is an effective medication for many patients not only with acute or persistent immune thrombocytopenia (ITP) but also for much more complicated patients with chronic ITP. In April 2021, data on the efficacy and safety of romiplostim from European clinical practice were published.

Source: Immune Thrombocytopenia 30. 11. 2021

News N9-GP in Previously Treated Pediatric Patients with Hemophilia B –⁠ Extended Follow-up

An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.

Source: Hemophilia with Movement 4. 10. 2023

News Risk Factors for Renal Cancer Formation After Kidney Transplantation

German authors in the below-cited work identified modifiable risk factors associated with the development of renal cell carcinoma (RCC) de novo in patients after kidney transplantation.

Source: Kidney Carcinoma 5. 11. 2021

News Incidence of Glaucoma or Suspected Glaucoma Within the First Year Post-Lensectomy in Children and Treatment Approach to These Patients

The aim of the study conducted by a team of authors from several American universities was to determine the approximate incidence of glaucoma or suspected glaucoma in children under 13 years old within the first year after lensectomy and to describe the management of care for these patients.

Source: Glaucoma 12. 2. 2020

News Romiplostim in ITP Treatment –⁠ Data from German Clinical Practice

Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.

Source: Immune Thrombocytopenia 2. 10. 2023

News Levothyroxine Substitution Depending on Patient Genotype

Careful titration of hormone dose leads to optimal dosing of replacement therapy for hypothyroidism. The authors of a cross-sectional study published in the Endocrine Journal examined the impact of polymorphisms in genes for proteins involved in thyroid hormone metabolism on the response to levothyroxine treatment in patients after thyroidectomy.

Source: Thyroid Disorders 7. 6. 2022

News Initiation of Sacubitril/Valsartan After Acute Decompensation of Chronic Heart Failure: The Sooner, the Better

The recently published analysis of data from the extended open-label follow-up of participants in the PIONEER-HF study clearly pointed out the difference in outcomes and prognosis of patients, which is led by the initiation of the combined drug during hospitalization compared to its initiation shortly after discharge.

Source: Chronic Heart Failure and Lipidology 27. 2. 2020

News Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma

Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the healthcare system, but also have an impact on the entire society. Patients with follicular lymphoma (FL) are also life partners, parents, relatives, and household members, and last but not least, they are also employees or service workers. How treatment success can reflect in these aspects is suggested by a German study.

Source: Non-Hodgkin Lymphomas and CLL 14. 11. 2020

News Recommended and Not Recommended Physical Activity for Individuals with Hemophilia

Physical activity is now considered a fundamental prerequisite for maintaining the health of individuals with hemophilia. The World Federation of Hemophilia (WFH) also recommends it to improve fitness and neuromuscular health. Numerous studies have shown that physical activity can help enhance the effectiveness of hemophilia treatment and prevent bleeding episodes. In older individuals, including those with hemophilia, a lack of physical activity increases the risk of developing diabetes, hypertension, dyslipidemia, obesity, and osteoporosis, along with subsequent fractures and complications associated with hemophilia.

Source: Hemophilia with Movement 25. 2. 2021